BACKGROUND: Stomatitis, including oral mucositis and ulcerations induced by HSV-reactivation are major sources of morbidity after high-dose (HD) chemotherapy and subsequent autologous hematopoietic stem cell transplantation (SCT). While increased synthesis of pro-inflammatory cytokines, such as interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-α)-as well as reactivation of viral infections have frequently been observed in this setting, data on their association with the severity of mucositis is limited. MATERIALS AND METHODS: Fifteen patients with Hodgkin's or non-Hodgkin's lymphoma receiving HD conditioning chemotherapy and autologous SCT were assessed with respect to oral pain and severity of stomatitis on day -6, 0, +5 to +7, +13 to +15, and +100. On the same dates, IL-1 and TNF-α were quantified in saliva and screening for a wide range of viral pathogens was carried out by cell culture and PCR and complemented by serological analyses. t Tests were used to assess potential associations between these variables. RESULTS: All but one patient had a positive HSV IgG titer at baseline. Reactivation as confirmed by HSV PCR was observed in seven patients (50%). There was a significant association between the presence of HSV in saliva samples and severity of stomatitis (t test, p = 0.015). The highest concentration of TNF-α and IL-1 coincided with the maximum intensity of stomatitis, but the association was not significant. CONCLUSION: We found a significant association between the presence of HSV in saliva samples and severity of stomatitis in patients receiving HD chemotherapy and subsequent autologous SCT. While acyclovir prophylaxis has become standard for patients undergoing allogeneic SCT, this issue has not been sufficiently explored for other chemotherapy regimens. Based on our findings, conduction of a well-powered controlled randomized trial may be warranted.
BACKGROUND:Stomatitis, including oral mucositis and ulcerations induced by HSV-reactivation are major sources of morbidity after high-dose (HD) chemotherapy and subsequent autologous hematopoietic stem cell transplantation (SCT). While increased synthesis of pro-inflammatory cytokines, such as interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-α)-as well as reactivation of viral infections have frequently been observed in this setting, data on their association with the severity of mucositis is limited. MATERIALS AND METHODS: Fifteen patients with Hodgkin's or non-Hodgkin's lymphoma receiving HD conditioning chemotherapy and autologous SCT were assessed with respect to oral pain and severity of stomatitis on day -6, 0, +5 to +7, +13 to +15, and +100. On the same dates, IL-1 and TNF-α were quantified in saliva and screening for a wide range of viral pathogens was carried out by cell culture and PCR and complemented by serological analyses. t Tests were used to assess potential associations between these variables. RESULTS: All but one patient had a positive HSV IgG titer at baseline. Reactivation as confirmed by HSV PCR was observed in seven patients (50%). There was a significant association between the presence of HSV in saliva samples and severity of stomatitis (t test, p = 0.015). The highest concentration of TNF-α and IL-1 coincided with the maximum intensity of stomatitis, but the association was not significant. CONCLUSION: We found a significant association between the presence of HSV in saliva samples and severity of stomatitis in patients receiving HD chemotherapy and subsequent autologous SCT. While acyclovir prophylaxis has become standard for patients undergoing allogeneic SCT, this issue has not been sufficiently explored for other chemotherapy regimens. Based on our findings, conduction of a well-powered controlled randomized trial may be warranted.
Authors: E Gluckman; J Lotsberg; A Devergie; X M Zhao; R Melo; M Gomez-Morales; M C Mazeron; Y Perol Journal: J Antimicrob Chemother Date: 1983-09 Impact factor: 5.790
Authors: R Saral; R F Ambinder; W H Burns; C M Angelopulos; D E Griffin; P J Burke; P S Lietman Journal: Ann Intern Med Date: 1983-12 Impact factor: 25.391
Authors: Jane L Liesveld; Camille N Abboud; J J Ifthikharuddin; Jeffrey E Lancet; Lucy A Wedow; Jamie Oliva; Carol G Stamm; Diane Nichols Journal: Biol Blood Marrow Transplant Date: 2002 Impact factor: 5.742
Authors: Richard M Logan; Andrea M Stringer; Joanne M Bowen; Ann S-J Yeoh; Rachel J Gibson; Stephen T Sonis; Dorothy M K Keefe Journal: Cancer Treat Rev Date: 2007-05-15 Impact factor: 12.111
Authors: Nicole Blijlevens; Matthias Schwenkglenks; Pamela Bacon; Alessandra D'Addio; Hermann Einsele; Johan Maertens; Dietger Niederwieser; Werner Rabitsch; Ann Roosaar; Tapani Ruutu; Harry Schouten; Rebecca Stone; Samuel Vokurka; Barry Quinn; Shaun McCann Journal: J Clin Oncol Date: 2008-02-11 Impact factor: 44.544
Authors: Sharon Elad; Vinisha Ranna; Anura Ariyawardana; Maria Elvira Pizzigatti Correa; Vanessa Tilly; Raj G Nair; Tanya Rouleau; Richard M Logan; Andres Pinto; Veronica Charette; Debbie P Saunders; Siri Beier Jensen Journal: Support Care Cancer Date: 2016-11-16 Impact factor: 3.603
Authors: T M Haverman; J E Raber-Durlacher; W M H Rademacher; S Vokurka; J B Epstein; C Huisman; M D Hazenberg; J J de Soet; J de Lange; F R Rozema Journal: Mediators Inflamm Date: 2014-04-10 Impact factor: 4.711